AXSM vs MRNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 21, 2026

AXSM

53.9
AI Score
VS
MRNA Wins

MRNA

58.3
AI Score

Investment Advisor Scores

AXSM

54score
Recommendation
HOLD

MRNA

58score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric AXSM MRNA Winner
Revenue 409.58M 534.00M MRNA
Net Income -115.86M -2.13B AXSM
Net Margin -28.3% -397.9% AXSM
Operating Income -113.00M -2.20B AXSM
ROE -139.1% -31.4% MRNA
ROA -15.2% -19.4% AXSM
Total Assets 761.45M 10.96B MRNA
Cash 319.85M 1.72B MRNA
Debt/Equity 1.42 0.09 MRNA
Current Ratio 1.43 2.29 MRNA
Free Cash Flow -54.22M -1.25B AXSM

Relative Price Performance (Last 90 Days)

AXSM 1M: -14.6% · 3M: -26.1% MRNA 1M: +26.0% · 3M: +132.3%

Current Technical Phase

AXSM

Markdown
Sell / avoid

Price below a falling SMA50 (slope -6.7%), weak momentum, RSI 29

RSI (14): 28.6 · Price: $179.25

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (47.6% over 20 days), RSI 66

RSI (14): 66.2 · Price: $190.01

Fundamentals Snapshot

Metric AXSM MRNA
Market Cap — —
Forward P/E 38.0 -39.7
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.5% 0.0%
Gross Margin 0.9% -0.7%
Operating Margin -0.2% -5.6%
EPS -3.75 -7.82
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, MRNA is currently the stronger investment candidate, winning 6 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.